

NICKEL REFERENCE EXPOSURE LEVELS (DRAFT)

Air Toxicology and Epidemiology Branch
Office of Environmental Health Hazard
Assessment
April, 2011



Authority

- The Office of Environmental Health Hazard Assessment (OEHHA) is required to develop guidelines for conducting health risk assessments under the **Air Toxics Hot Spots Program (Health and Safety Code Section 44360 (b) (2))**.
- Consideration of possible differential effects on the health of infants, children and other sensitive subpopulations is mandated by the **Children's Environmental Health Protection Act (Senate Bill 25, Escutia, chapter 731, statutes of 1999, Health and Safety Code Sections 39669.5 *et seq.*)**.



Summary

- **Nickel (II) causes a variety of non-carcinogenic toxic effects including occupational contact dermatitis, occupational asthma, and reproductive toxicity in humans.**
- **Studies in experimental animals exhibit immune suppression, nephrotoxicity, pneumotoxicity, perinatal mortality and altered gene expression.**
- **The most sensitive effects appear to be in the lung and immune system.**



Nickel as a Toxic Air Contaminant

- High potential exposure to nickel and nickel compounds:
 - Widespread occurrence.
 - Numerous uses.
- Effects leading to differential impacts on infants and children:
 - Adverse impacts on the respiratory and immune systems including asthma (see Sections 5,6,8 and 9).
 - Increased perinatal mortality and reduced birth weight observed in animals studies of reproductive toxicity (see Section 7.2).
- **OEHHA therefore recommends that nickel be identified as a toxic air contaminant which may disproportionately impact children, pursuant to Health and Safety Code, Section 39669.5(c).**



Ni(II) sources

- **Air:** The annual statewide average ambient air concentration of nickel for 2002 was 4.5 ± 4.1 SD ng Ni/m³ (CARB, 2008).
- **Soil:** Soils concentrations throughout the U.S. ranged from <5 to 700 ppm, with a geometric mean of 13.0 ± 2.31 . (U.S. Geological Survey)
- **Drinking water:** generally contains nickel at concentrations ranging from 0.55 to 25 µg Ni/L.
- **Food:** The mean and median concentrations of nickel in combined dietary solids and liquids were 47 and 43 µg Ni/kg, respectively.



Toxicokinetics

- **Oral absorption** 0.5 to 40 % based on water solubility, vehicle (water or food), fasted or fed.
- **Inhalation:** 50% of soluble NiCl_2 cleared from lungs in 3 days. Insoluble forms cleared much more slowly, e.g., NiO $T_{1/2}$'s in lung of 12 and 21 mo depending on particle size.
- **Distribution** in all tissues dependent on water solubility and dose. For NiSO_4 , kidney > testes > brain > spleen > heart > liver.



Toxicokinetics (Cont.)

- **Excretion:** Most nickel absorbed from diet and environmental media is rapidly excreted in urine.
 - First order elimination half lives :
6 and 50 hr in rats, 8 and 83 hr in rabbits.
- **Excretion:** Sweat and milk possible excretion routes in humans.
- **Models:** Biokinetic, PBPK, Lung Deposition-Clearance, Keratinocyte- Cytokine Response, Tracheobronchial Epithelial Cell.



Acute Toxicity in Humans

- **32 Workers consumed 0.5 to 2.5 g Ni(II) as chloride and sulfate in drinking water.**
 - 20 had nausea, vomiting, abdominal discomfort, giddiness, lassitude, headache, cough and shortness of breath, for a few hours to several days (Sunderman et al., 1988).
- **7 metal plating workers with occupational asthma tested for lung function with 30 min exposure to 0.3 mg/m³ NiSO₄.**
 - 6/7 had significantly decreased FEV₁ (>15%) (Cirila et al., 1985).



Acute Toxicity in Animals

- **Water soluble Ni(II) compounds** more acutely toxic than water insoluble by oral route
- **NiSO₄ and Ni acetate** single dose oral LD₅₀'s ranged from 39 to 141 mg/kg in rats and mice.
- **NiO and Ni₃S₂**
 - single oral LD₅₀'s > 3000 mg/kg in rats and mice.
 - Subacute inhalation exposure (6hr/d x 5d/wk, 12 days) to 5 or 10 mg Ni₃S₂/m³ caused lung pathology, mortality at higher dose in mice and rats.




Acute Toxicity in Animals (Cont.)

- **Immunotoxicity in mice (Graham et al., 1975, 1978).** Six-week old mice exposed to 0 to 490 $\mu\text{g}/\text{m}^3$ NiCl_2 ($\leq 3 \mu\text{m}$) for two hours. Exposed animals gave significant decrease in antibody-forming cells after antigen challenge. LOAEL = 250 $\mu\text{g Ni}/\text{m}^3$, NOAEL $\approx 100 \mu\text{g Ni}/\text{m}^3$, BMDL = 164.6 $\mu\text{g Ni}/\text{m}^3$ (-100 plaques/1E6 cells)



Linear Model with 0.95 Confidence Level



11:30 11/21 2008



Reproductive & Developmental Toxicity in Animals

- Two generation reproduction study in rats (0, 0.22, 0.56, 1.12, or 2.23 mg Ni/kg-d) by NiSO₄ aqueous gavage (min. of 70 days of treatment, NiPERA 2000b).
 - Dose related increases in perinatal mortality.
 - LOAEL = 2.23 mg Ni/kg-d
 - NOAEL = 1.12 mg Ni/kg-d
- Spermatotoxicity in mice (Pandey & Srivastava, 2000). Male mice orally administered (0, 5, 10, 20 mg NiSO₄ or NiCl₂/kg-d) x 5d/wk x 35 d.
 - Significant decreases in sperm count at 20 and motility at 10 and 20 mg/kg-d.
 - Increases in abnormal sperm shapes at 10 and 20 mg/kg-d.
 - BMDL_{1SD} = 2.91 mg/kg-d for sperm motility (NiSO₄) and 0.46 (NiSO₄) and 0.34 (NiCl₂) mg/kg-d for sperm abnormality.



Reproductive & Developmental Toxicity in Humans

- Spontaneous abortion (SA) case-control study of Vaktsjold et al., 2008b) in female nickel refinery workers.
 - Odds ratios for association between Ni exposure and SA was 1.38 (95% C.I. 1.04-1.84) (unadjusted) and 1.14 (95% C.I. 0.95-1.37) (adjusted). Possibly a weak excess risk.
- Semen quality in 57 workers exposed to nickel and chromium and 57 unexposed controls (Danadevi et al., 2003) .
 - Sperm concentration reduced in exposed group 14.5E6/mL vs. 62.8E6/mL .
 - Reduction in rapid linear sperm motility and increase in sperm tail defects correlation with increased blood nickel in exposed workers. Negative correlation with blood Cr.



Chronic Toxicity Human Studies

- Lung radiographic abnormalities (pulmonary fibrosis, PF) in workers exposed to airborne nickel (Berge & Skyberg, 2003).
 - OR for PF and soluble Ni was 4.34 (95% C.I. 1.75-10.77) (unadjusted) and 2.24 (95% C.I. 0.82- 6.16) (adjusted for age, smoking, asbestos, sulfidic Ni).
 - Sulfidic Ni PF OR was 5.06 (1.70-15.09) (unadjusted) and 2.04 (0.54-7.70) (adjusted).
 - BMDL₀₁ = 0.35 soluble and 0.19 sulfidic (mg Ni/m³)yr.
- Results indicate dose-response for cumulative Ni exposure and PF. Mean and median exposure periods were 21.8 and 21.9 yr, respectively.



Chronic Toxicity in Animal Studies

- Oller et al., (2008) inhaled Ni metal in rats (0, 0.1, 0.4, or 1.0 mg Ni/m³, MMAD = 1.8µm) 6hr/d x 5d/wk x 24 mo. No NOAEL.
 - Respiratory lesions: alveolar proteinosis , alveolar histiocytosis, chronic inflammation, bronchiolar-alveolar hyperplasia and bronchial lymph node infiltrate.
- NTP (1994c) chronic study of NiSO₄.6H₂O in rats. Exposures 0, 0.03, 0.06, or 0.11 mg Ni/m³, as above.
 - Lung inflammatory lesions, macrophage hyperplasia, and nasal epithelial atrophy seen at 0.06 mg Ni/m³ and above.
 - LOAEL = 60 µg/m³, NOAEL = 30 µg/m³, BMDL₀₅ = 30.5 µg/m³.



Chronic Toxicity in Animal Studies

- NTP(1994a) chronic study of NiO in mice exposed to (0, 1.0, 2.0, or 4.0 mg Ni/m³) 6hr/d x 5d/wk x 24 mo.
 - Lung lesions similar to other studies. Bronchial lymph-node hyperplasia evident in all Ni-exposed animals.
 - NOAEL not observed, LOAEL 1.0 mg/m³, BMDL₀₅ = 117 µg Ni/m³ (alveolar proteinosis).



Acute REL

- Study: Cirila et al. (1985) 7 metal plating volunteers with occupational asthma
- Exposure: $0.3 \text{ mg NiSO}_4 \cdot 6\text{H}_2\text{O}/\text{m}^3$ ($67 \text{ } \mu\text{g Ni}/\text{m}^3$) for 30 minutes
- LOAEL = $67 \text{ } \mu\text{g Ni}/\text{m}^3$ (30 min) for FEV1
- NOAEL = Not observed
- LOAEL = $33 \text{ } \mu\text{g Ni}/\text{m}^3$ (1 hr adjustment)
- LOAEL UF = 10
- Intraspecies UF = $\sqrt{10}$
- Cumulative UF = 30
- aREL = $33/30 = 1.1 \text{ } \mu\text{g Ni}/\text{m}^3$



8-Hour REL

- Study: Graham et al. (1978) Supported by NTP 1994c
- Study Population: Female mice
- Exposure: Inhalation of 100 to 490 $\mu\text{g NiCl}_2/\text{m}^3$ for 2 hours
- Effect: Depressed antibody response to sheep red blood cells
- LOAEL = 250 $\mu\text{g Ni}/\text{m}^3$
- BMDL = 165 $\mu\text{g Ni}/\text{m}^3$ (for -100 plaques/million cells)
- NOAEL = 100 $\mu\text{g Ni}/\text{m}^3$ (questionable)
- BMDL = 82 $\mu\text{g Ni}/\text{m}^3$ (extrapolated to 8 hours)
- LOAEL UF = $\sqrt{10}$ for BMR analysis
- Interspecies UF = 10
- Intraspecies UF = 30 (10 PD x $\sqrt{10}$ PK)
- Cumulative UF = 1000
- 8-Hr REL = $82/1000 = 0.08 \mu\text{g Ni}/\text{m}^3$



Chronic REL Ni and Ni Compounds Except NiO

- Study: NTP 1994c
- Study Population: Male and female rats
- Exposure: Discontinuous inhalation 0, 0.12, 0.25, or 0.5 mg NiSO₄•6H₂O/m³ (0,0.03, 0.06, 0.11 mg Ni/m³), 6hr/d x 5d/wk x 104 wk
- Critical Effects: Pathological changes on lung, lymph nodes and nasal epithelium
- LOAEL = 60 µg Ni/m³
- NOAEL = 30 µg Ni/m³
- BMDL = 30.5 µg Ni/m³
- Average experimental concentration = 5.4 µg Ni/m³
- Human equivalent Concentration = 1.4 µg Ni/m³ (MPPD2)



cREL Ni and Ni compounds except NiO (Cont.)

- Interspecies UF = $\sqrt{10}$
- Intraspecies UF = 30 (10PD x $\sqrt{10}$ PK)
- Cumulative UF = 100
- cREL = $1.4/100 = 0.014 \mu\text{g Ni/m}^3$



Chronic REL NiO

- Study: NTP 1994a
- Study Population: Male and female mice (57-69/group)
- Exposure: Discontinuous inhalation (0, 1.0, 2.0, 4.0 mg Ni/m³) 6hr/d x 5d/wk x 104 wk
- Critical Effects: Pathological changes in the lung including pulmonary inflammation and alveolar proteinosis
- LOAEL = 1.0 mg Ni/m³
- BMDL = 117 µg/m³ (5%, alveolar proteinosis)
- Average Experimental Concentration = 20.9 µg Ni/m³



cREL NiO (Cont.)

- Human Equivalent Concentration = $2.0 \mu\text{g Ni/m}^3$ (from Hsieh et al., 1999)
- Interspecies UF = $\sqrt{10}$
- Intraspecies UF = 30 (10 PD x $\sqrt{10}$ PK)
- Cumulative UF = 100
- cREL = $2.0/100 = 0.02 \mu\text{g Ni/m}^3$



Oral Chronic REL

- Study: NiPERA (2000a,b)
- Study Population : Rats (Sprague-Dawley)
- Exposure: Aqueous gavage with NiSO₄
- Critical Effects: Perinatal mortality in two generation study
- LOAEL = 2.23 mg Ni/kg-d
- NOAEL = 1.12 mg Ni/kg-d
- Average exposure = 1.1 mg/kg-d
- Human equivalent = 1.1 mg/kg-d



Oral cREL (Cont.)

- LOAEL UF = 1
- Interspecies UF = 10
- Intraspecies UF = 10
- Cumulative UF = 100
- Oral cREL = $1.1/100 = 0.011$ mg Ni/kg-d



Overall RELs Summary

- Acute REL = $1.1 \mu\text{g Ni/m}^3$ FEV1 decrease
- 8-Hr REL = $0.08 \mu\text{g Ni/m}^3$ Immunotoxicity
- Chronic REL = $0.014 \mu\text{g Ni/m}^3$ Lesions in lung, lymph nodes and nasal epithelium, alveolar proteinosis (Ni and Ni compounds except NiO)
- Chronic REL (NiO) = $0.02 \mu\text{g Ni/m}^3$ Alveolar proteinosis
- Oral REL = $11 \mu\text{g/kg-d}$ Perinatal mortality (Same as basis for drinking water PHG)



NiPERA Letter to SRP, April 19, 2011

- Dosimetry Adjustment: OEHHA calculates the HEC based solely on the ratio of *deposition fractions* in humans and rats. A more precise calculation can be made based on the ratio of *deposited doses*.
- OEHHA : DAF (NiSO₄) = (Fr)_a/(Fr)_h = (0.089/0.348) = 0.264
- NiPERA: RDDRr (NiSO₄) = (SA)_h/(SA)_a x (Ve)_a/(Ve)_h x (Fr)_a/(Fr)_h = (54/0.34)(214.2/13,800)(0.089/0.348) = 0.554
- RDDRr normalization factors are default adult values not child whereas human Fr is mean of all age-specific values.
- All child values show higher fractional depositions than adult. Child range = 0.32 to 0.4 vs. 0.25 for adult.



NiPERA Letter to SRP (Cont.)

- Alternative approach with MPPD2 Model. Compare retention of particles for comparable periods of age in deposition/clearance simulations: 3mo (2weeks); 3yr(6 mo); 9yr(1yr), 14 yr(1yr), 21Yr(2yr), Adult rat (90d). Exposure of 120 $\mu\text{g}/\text{m}^3$ x 6 hr/d x 5d/wk x weeks above. Metric: Specific Retention(SR) $\mu\text{g NiSO}_4/\text{d}/\text{m}^2$ alveolar surface area.
- Preliminary SR values: 3mo = 2.10; 3 yr = 1.12; 9yr = 0.91; 14yr = 0.86; 21yr = 0.29; Rat = 0.33.
- $\text{DAF} = (\text{SR})_a / (\text{SR})_h \times (\text{Fr})_a / (\text{Fr})_h = 0.465 \times 0.264 = 0.12$



Chemical Forms of Ni(II)

- Ni, nickel metal
- NiO, nickel oxide
- NiCl₂, nickel chloride
- NiSO₄·6H₂O, nickel sulfate hexahydrate
- Ni₃S₂, nickel subsulfide
- NiS, nickel sulfide
- Ni, NiO, Ni₃S₂ are insoluble in water
- NiSO₄·6H₂O, NiCl₂ are soluble in water



Uses and Exposure Sources

- About 40 % of nickel used in stainless steel, permanent magnets, and alloys
- About 20% used as NiSO_4 and Ni(OH)_2 in electroplating, batteries, dyes, catalysts
- Most common airborne exposures to nickel compounds are to insoluble nickel compounds
 - elemental nickel, nickel sulfide, nickel oxides from dusts and fumes

